Deferred Tax Assets, Operating Loss Carryforwards of ELITE PHARMACEUTICALS INC /NV/ from 31 Mar 2014 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Mar 2014 to 31 Mar 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Mar 2025 was $10,664,000, a 31% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $10,664,000 -$4,869,000 -31% 31 Mar 2025 10-K 30 Jun 2025 2025 FY
Q1 2024 $15,533,000 -$2,080,000 -12% 31 Mar 2024 10-K 30 Jun 2025 2025 FY
Q1 2023 $17,613,000 31 Mar 2023 10-K 01 Jul 2024 2024 FY
Q1 2018 $19,213,000 -$10,702,000 -36% 31 Mar 2018 10-K 14 Jun 2018 2018 FY
Q1 2017 $29,915,000 +$2,882,000 +11% 31 Mar 2017 10-K 14 Jun 2018 2018 FY
Q1 2016 $27,033,000 +$27,008,453 31 Mar 2016 10-K 14 Jun 2018 2018 FY
Q1 2015 $24,547* -$19,788,453 31 Mar 2015 10-K 14 Jun 2017 2017 FY
Q1 2014 $19,813,000 31 Mar 2014 10-K 15 Jun 2016 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.